This program is intended for healthcare professionals caring for patients with epilepsy, including neurologists, psychiatrists, nurse practitioners, physician associates/physician assistants, nurses, and pharmacists.
The goal of this program is to improve the knowledge, competence, and comfort with development of seizure action plans including rescue medications in order to optimize treatment for patients with epilepsy who experience acute repetitive seizure episodes.
Upon completion of this activity, participants should be able to:
Justify the need for a seizure action plan based on disease and patient-specific characteristics
Identify key elements of a seizure action plan
Differentiate characteristics of pharmacologic options for breakthrough seizures
Formulate strategies for counseling patients, family members, and caregivers on how to use rescue medications
Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial conflicts of interest (COI) they may have with ineligible companies. All relevant COI are thoroughly vetted and mitigated according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.
The faculty reported the following relevant financial relationships or relationships to products or devices they have with ineligible companies related to the content of this educational activity:
Jacqueline French, MD
Department of Epilepsy/Neurology
NYU Grossman School of Medicine
New York, New York
Jacqueline French, MD: consultant/advisor/speaker: Epilepsy Foundation, Epilepsy Study Consortium; consultant/advisor/speaker (paid to institution): Aeonian/Aeovian, Agrithera, Alterity Therapeutics Limited, Anavex, Angelini Pharma, Arkin Holdings, Arvelle Therapeutics, Athenen Therapeutics/Carnot Pharma, Autifony Therapeutics Limited, Baergic Bio, Beacon Biosignals, Biogen, Biohaven Pharmaceuticals, BioMarin Pharmaceutical, BioXcel Therapeutics, Bloom Science, BridgeBio Pharma, Camp4 Therapeutics Corporation, Cerebral Therapeutics, Cerevel, Coda Biotherapeutics, Cognizance Biomarkers, Corlieve Therapeutics, Crossject, Eisai, Eliem Therapeutics, Encoded Therapeutics, Engage Therapeutics, Engrail, Epalex, Epihunter, Epiminder, Epitel, Equilibre BioPharmaceuticals, Genentech, Greenwich Biosciences, Grin Therapeutics, GW Pharma, Janssen, Jazz, Knopp Biosciences, Korro Bio, Lipocine, LivaNova, Longboard Pharmaceuticals, Lundbeck, Marinus, Merck, NeuCyte, Neumirna Therapeutics, Neurocrine, Neuroelectrics USA Corporation, Neuronetics, Neuropace, NxGen Medicine, Ono Pharmaceutical, Otsuka Pharmaceutical Development, Ovid Therapeutics, Paladin Labs, Passage Bio, Pfizer, Praxis, PureTech LTY, Rafa Laboratories Ltd, Rapport Therapeutics, Receptor Holdings, Sage Therapeutics, SK Life Sciences, Sofinnova, Stoke, Supernus, Synergia Medical, Takeda, Third Rock Ventures LLC, UCB, Ventus Therapeutics, Xenon, Xeris, Zogenix, Zynerba; researcher: Andrews Foundation, Eisai, Engage, Lundbeck, Pfizer, SK Life Science, Sunovion, UCB, Vogelstein Foundation.
Pavel Klein, MD, FAAN, FAES
Department of Neurology
The George Washington University
Mid-Atlantic Epilepsy and Sleep Center
Pavel Klein, MD, FAAN, FAES: consultant/advisor/speaker: Abbott, Angelini, Aucta Pharmaceuticals, Eisai, Equilibre, Neurelis, OB Pharma, SK Life Sciences, Stratus, Sunovion, UCB Pharma, UNEEG, UniQure; owner: PrevEP.
The planners and content peer reviewers from Clinical Care Options, LLC do not have any relevant financial relationships to disclose, except Gabrielle Giacona and Amanda Zimmerman, PA-C, as noted below:
Gabrielle Giacona: individual publicly traded stocks/stock options: AstraZeneca, Moderna.
Amanda Zimmerman, PA-C: consultant/advisor/speaker: Averitas; researcher: Collegium.
Participation in this self-study activity should be completed in approximately 1 hours. To successfully complete this activity and receive credit, learners must follow these steps during the period from July 27, 2023, through July 26, 2024:
You must receive a test score of at least 65 and respond to all evaluation questions to receive a certificate. After submitting the evaluation, you may access your online certificate by selecting the certificate link on the confirmation page. Records of all CME/CE activities completed can be found on the "My Certificates" page. There are no costs/fees for this activity.
The program has been made available online.
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.
The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
Joint Accreditation Statement
In support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.
Physician Continuing Medical Education
CCO designates this enduring material for a maximum of 1 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Nursing Continuing Professional Development
The maximum number of hour awarded for this Nursing Continuing Professional Development activity is 1 contact hour.
Physician Associate/Physician Assistant Continuing Medical Education
Clinical Care Options has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1 AAPA Category 1 CME credit. Approval is valid until July 26, 2024. PAs should only claim credit commensurate with the extent of their participation.
Continuing Pharmacy Education
CCO designates this continuing education activity for 1 contact hour (0.1 CEUs) of the Accreditation Council for Pharmacy Education.
Universal Activity Number - JA4008176-0000-23-193-H01-P
Type of Activity: Application
Upon successfully completing the post-test with a score of 65 and the activity evaluation form, transcript information will be sent to the NABP CPE Monitor Service within 60 days.